Glaucoma Center investigators use CRISPR/Cas9 technology to develop new glaucoma treatments

Fri, 10/06/2017 - 10:00

A research team led by Dr. Val Sheffield and Dr. Ankur Jain developed a genome editing (CRISPR/Cas9) approach to treat glaucoma caused by mutations in the myocilin gene. In 1997, Iowa Glaucoma Center investigators discovered that mutations in myocilin were the most common known cause of glaucoma and are responsible for 1 in 25 cases. In the current study, investigators report successfully correcting myocilin mutations to prevent high eye pressure and glaucoma in mice. Read more about this research here.